Coronary Bypass | Medical XPRT
Articles & Whitepapers
-
EluNIR First-in-Patient Implantation- Case Study
Background This paper outlines the first in-patient implantation of the EluNIR™ ridaforolimus eluting elastomeric stent (Medinol Ltd.). This complex case involved a patient with a flow-limiting lesion in a native coronary artery post bypass surgery. The new EluNIR stent system includes a stent with a low metal footprint which comprises struts of variable width: ultra-narrow struts having ...
-
EluNIR DES in a Challenging Case - Case Study
Background: This paper describes a challenging case of implantation of the EluNIR™ Ridaforolimus eluting elastomeric stent (Medinol Ltd.). This complex case involved a patient with a ...
News
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 ...
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug
Xeltis accelerating clinical trial program
Equipment & Solutions
-
Showcase
Rapamycin Target Eluting Coronary Stent System
Extraordinary Deliverability. Ultra Low Profile. Target Eluting Technology of Firehawk.